Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Japanese Drug Production Could Shrink to 6.8 Trillion Yen in 2024: Yano Research Institute
May 10, 2017
- BIKEN, Mitsubishi Tanabe Reach Final Agreement on Vaccine Joint Venture Slated to Begin Operation in September
May 10, 2017
- Daiichi Sankyo Starts Edoxaban Clinical Study in AF Patients following TAVI
May 10, 2017
- Eisai Suffers Setback in US Patent Litigation over Aloxi
May 9, 2017
- Mitsubishi Tanabe’s ALS Med Gets FDA Greenlight
May 9, 2017
- Sales Rep Survey - 1: Foreign Drug Makers’ Downsizing Drive Unabated
May 9, 2017
- 60% of Drug Makers Increase New Grad Hires in FY2017, Otsuka Tops List: Jiho Tally
May 9, 2017
- Brexpiprazole Delivers Mixed Results on AD Agitation: Otsuka, Lundbeck
May 8, 2017
- Debiopharm’s Appeal on Elplat Patent Suit Dismissed: Nichi-Iko
May 8, 2017
- Takeda Gets FDA Nod for Ariad’s ALK Hopeful Brigatinib
May 8, 2017
- Keytruda Filed in Japan for Urothelial Cancer: MSD
April 28, 2017
- Harvoni Filed for Genotype 2 Hepatitis C: Gilead Japan
April 28, 2017
- Takeda Joins Hands with Harrington Institute on Rare Disease Therapeutics
April 28, 2017
- Pfizer Files Japan NDA for ALL Treatment
April 28, 2017
- Certican Filed in Japan for Liver Transplant Rejection: Novartis
April 28, 2017
- Daiichi Sankyo to More than Triple ADC Production Capacities by 2021
April 28, 2017
- Kyowa Kirin Submits Regpara Successor in Japan
April 28, 2017
- Astellas Looking to Xtandi Growth Outside US: President
April 28, 2017
- Astellas Sales Dip 4.4% on Forex Moves, Japan Biz Dented by Price Cuts
April 28, 2017
- Otsuka, Akebia Expand Licensing Pact for Anemia Med Vadadustat
April 27, 2017
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…